2005
DOI: 10.21236/ada495556
|View full text |Cite
|
Sign up to set email alerts
|

Immunization to Protect the U.S. Armed Forces: Heritage, Current Practice, Prospects

Abstract: Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and R… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 143 publications
(202 reference statements)
0
2
0
Order By: Relevance
“…The Army has long taken adult vaccination very seriously. 8,9 It was a casual Saturday conversation that sparked my lifelong efforts with vaccines. Who could have known?…”
Section: The Big Picture Is Public Healthmentioning
confidence: 99%
“…The Army has long taken adult vaccination very seriously. 8,9 It was a casual Saturday conversation that sparked my lifelong efforts with vaccines. Who could have known?…”
Section: The Big Picture Is Public Healthmentioning
confidence: 99%
“…Part of Lilly’s calculus included the relative rarity of documented pneumococcal disease and the difficulty of confirming its diagnosis. This problem was mitigated by the self‐funded pneumococcal research programme that Merck Sharp and Dohme (MSD) began in 1970, building on its expertise acquired in developing and producing a meningococcal polysaccharide vaccine for the US Army [19,66]. The companies developed vaccine formulations of various valencies, but only after testing each individual polysaccharide for safety and immunogenicity.…”
Section: Randomized Clinical Trials Of 1970smentioning
confidence: 99%